A comprehensive review highlights how CAR-T cell therapy is pushing beyond blood cancers into solid tumors and autoimmune indications, mapping the approvals and emerging strategies driving the shift. The review notes that by end of 2024, 12 CAR-T products had gained approval in the U.S., framing the momentum that sponsors and partners are now trying to replicate in harder-to-treat disease settings. For solid tumors, the report emphasizes the field’s ongoing effort to overcome barriers such as tumor microenvironment suppression and antigen constraints, while for autoimmune disease it points to immunologic safety considerations that have shaped early clinical designs. The review’s value for industry readers is its consolidation of the breadth of the CAR-T attempt—what has moved forward and the nature of the remaining translational gaps. The sector impact is clear: CAR-T pipeline prioritization is likely to keep expanding toward combination regimens and next-generation construct formats, with developers using review-driven clarity to guide trial design focus.